

Unaudited Financial Statements for the Year Ended 30 April 2021

for

Brighton Pharma Ltd

Contents of the Financial Statements
for the Year Ended 30 April 2021

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

DIRECTOR: Mrs S A R Al-Abboodi

REGISTERED OFFICE: 2nd Floor, Flat 20, Marsworth House
Hatton Road
Wembley
United Kingdom
HA0 1QY

REGISTERED NUMBER: 11304656 (England and Wales)

ACCOUNTANTS: Williams Chartered Accountants
Jade House
67 Park Royal Road
London
NW10 7JJ

Balance Sheet
30 April 2021

	Notes	30.4.21 £	£	30.4.20 £	£
FIXED ASSETS					
Tangible assets	4		509		679
CURRENT ASSETS					
Cash at bank and in hand		100		400,396	
CREDITORS					
Amounts falling due within one year	5	<u>11,717</u>		<u>409,052</u>	
NET CURRENT LIABILITIES			<u>(11,617)</u>		<u>(8,656)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>(11,108)</u>		<u>(7,977)</u>
CAPITAL AND RESERVES					
Called up share capital	6		100		100
Retained earnings			<u>(11,208)</u>		<u>(8,077)</u>
SHAREHOLDERS' FUNDS			<u>(11,108)</u>		<u>(7,977)</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2021 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 16 December 2021 and were signed by:

Mrs S A R Al-Abboodi - Director

Notes to the Financial Statements
for the Year Ended 30 April 2021

1. **STATUTORY INFORMATION**

Brighton Pharma Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. **ACCOUNTING POLICIES**

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc - 25% on reducing balance

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. **EMPLOYEES AND DIRECTORS**

The average number of employees during the year was NIL (2020 - 1).

Notes to the Financial Statements - continued
for the Year Ended 30 April 2021

4. **TANGIBLE FIXED ASSETS**

	Plant and machinery etc £
COST	
At 1 May 2020	
and 30 April 2021	<u>881</u>
DEPRECIATION	
At 1 May 2020	202
Charge for year	<u>170</u>
At 30 April 2021	<u>372</u>
NET BOOK VALUE	
At 30 April 2021	<u>509</u>
At 30 April 2020	<u>679</u>

5. **CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	30.4.21	30.4.20
	£	£
Net wages creditor	-	66
Directors' current accounts	9,917	408,535
Accrued expenses	<u>1,800</u>	<u>451</u>
	<u>11,717</u>	<u>409,052</u>

6. **CALLED UP SHARE CAPITAL**

Allotted, issued and fully paid:				
Number:	Class:	Nominal	30.4.21	30.4.20
		value:	£	£
100	Ordinary Class A	1	<u>100</u>	<u>100</u>

7. **ULTIMATE CONTROLLING PARTY**

The controlling party is Mrs S A R Al-Abboodi.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.